Endocrine signaling research
CJC-1295 No DAC
Lyophilisiertes Peptid zur Forschung zu endokrinen Signalen zur Systemüberprüfung
CJC-1295 No DAC is a short-acting GHRH analog studied as a pituitary GH-axis signaling reference.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesNur für Laborforschungszwecke. Nicht für den menschlichen oder veterinärmedizinischen Gebrauch bestimmt. Nicht zur Diagnose, Behandlung, Heilung, Linderung oder Vorbeugung von Krankheiten bestimmt.
Verschlossen, kalt, trocken und vor Hitzeschwankungen geschützt aufbewahren. Bestätigen Sie die produktspezifische Lagerung bei der Ankunft.
Verpackt für Transportstabilität mit Bestellunterstützung für Routen bei warmem Wetter.
Batch-linked certificate support is available through the documentation desk.
Forschungskontext
CJC-1295 No DAC Forschungsprofil
CJC-1295 No DAC is used as a shorter-acting GHRH analog reference in pituitary GH-axis research. Studies focus on GHRH-receptor activation, stimulated GH release, pulse timing, downstream IGF-1 markers, and comparisons with longer-acting analogs. The “No DAC” designation separates this material from CJC-1295 versions designed with a drug-affinity complex for albumin binding and prolonged exposure. It is generally selected when the experimental design values shorter signaling windows or direct comparison with sermorelin and secretagogue compounds. Nomenclature for modified GRF and CJC-related peptides can vary, so sequence identity, amount, and batch documents are important parts of product selection.
Vorgeschlagener Mechanismus
A short-acting GHRH-receptor agonist concept, often associated in commerce with modified GRF(1-29). GHRH receptor activation increases cyclic AMP in pituitary somatotrophs and promotes pulsatile growth-hormone release.
In Studien berichtete Effekte
- GHRH analog studies report acute increases in GH release and downstream IGF-1-related signaling, depending on analog and exposure.
- Shorter exposure is expected to produce a different release profile from albumin-binding CJC-1295 with DAC.
- The label "CJC-1295 No DAC" is used inconsistently and may not describe the same sequence studied under the original CJC-1295 name.
Häufige Forschungsendpunkte
Sequence confirmation, GHRH receptor activity, cyclic AMP, GH pulse amplitude and duration, IGF-1, pituitary responsiveness, degradation, and comparison with DAC-modified material.
Evidenz und Grenzen
GHRH biology is established, but direct evidence is weakened by naming and identity ambiguity. Sequence and batch documentation are especially important.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
GH axis Forschungspeptid
CJC-1295 with DAC
CJC-1295 with DAC is a longer-acting GHRH analog studied for extended GH-axis signaling and albumin-binding pharmacology.
- Form
- Lyophilisiertes Pulver
- Menge
- 5 mg
Preisspanne: 49.99 $ bis 212.99 $ Ausführung wählen Dieses Produkt weist mehrere Varianten auf. Die Optionen können auf der Produktseite gewählt werden